about
‘Global warming’ to Mycobacterium avium subspecies paratuberculosisPrimary treatment of Crohn’s disease: combined antibiotics taking center stageTherapeutic faecal microbiota transplantation: current status and future developmentsTreating Clostridium difficile infection with fecal microbiota transplantationFecal microbiota transplantation: indications, methods, evidence, and future directionsFecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and BeyondTreatment of ulcerative colitis using fecal bacteriotherapyFecal microbiota transplantation and emerging applicationsDurable alteration of the colonic microbiota by the administration of donor fecal floraTherapeutic potential of fecal microbiota transplantationSelective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. paratuberculosis infected Crohn's diseaseProbiotics under the regulatory microscope.Mycobacterium avium ss paratuberculosis-associated diseases: piecing the Crohn's puzzle together.Donor Recruitment for Fecal Microbiota Transplantation.Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead.Gastroenterologist perceptions of faecal microbiota transplantation.Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study.Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals.Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.Cholecystokinin and gallbladder contraction: effect of CCK infusion.The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection.Lactoferrin: milking ulcers?How effective are quadruple therapies as first-line H. pylori eradication therapies?Is Crohn's disease ready for fecal microbiota transplantation?Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.Selective reduction of anti-Helicobacter pylori IgG subclass antibody in gastric carcinoma.Could fecal microbiota transplantation cure all Clostridium difficile infections?Radioimmunoassay of cholecystokinin in human plasma.Helicobacter pyloriEradication with Doxycycline—Metronidazole—Bismuth Subcitrate Triple TherapyPhagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel diseaseComment on 2018 ACG Clinical Guideline: Antibiotics in Crohn's DiseaseSpecific Bacteria and Metabolites Associated with Response to Fecal Microbiota Transplantation in Patients with Ulcerative ColitisHelicobacter pylori reinfection 4 years post-eradicationCholelitholysis using methyl tertiary butyl etherRapid dissolution of gallstones by methyl tert-butyl ether. Preliminary observationsMotilin and migrating myoelectric complexes in the pig and the dogShift of the gastric T-cell response in gastric carcinoma
P50
Q22241305-DA7E3E7C-EB8E-438D-B5FC-CD1D37F69831Q22241483-0A86F5E7-9626-4E19-9644-BF91A00A82D9Q24629302-9F891027-1D3A-488E-99D2-4171B42734DAQ24634294-39200A5E-3267-4709-96BA-023B15A54C57Q26830134-821A22CB-436C-4456-8A4D-F3AF362CE9CDQ28084737-5F5A96AA-0A6A-4A16-94FF-CEF014A5767DQ28179819-AAAA45A8-8816-4665-8559-1AD999FA80CFQ28255756-9ED1E56E-F471-41C3-8401-4BD49BBE093FQ28290783-77B38F0F-2785-49FA-A9DB-B4F601C45FCDQ28298108-97DB246B-1BA6-4417-9B5C-12DF45BE90C0Q29040489-76177E0F-FDC9-4F62-9AD4-E7796BAD7718Q33226168-708528BB-6441-4E9F-A179-C30F1B768953Q33354058-D9D3284E-866B-4CE0-945B-A98D14A0466BQ35662258-3DDEB301-9F62-49BE-BCE6-20F33AB4AC6DQ35790385-DE824C94-372F-46CD-9D1C-ACC37ED6147DQ36145301-713CB9F6-5A62-4439-B260-4CE472C51118Q37604655-DDAA2269-D0E6-4ACD-80F1-A9B4D80260C3Q38755858-7023149E-B8A1-4CCF-9ACA-89322CABD7E3Q40559905-0C589A53-68A3-456E-9AE3-366D959C7FF5Q41131222-85DBD7DF-9482-41F9-ABE5-1343206B5EF7Q41194710-5F57EEF8-7837-4EC5-8F77-8122503AE4F8Q41553408-3937FE26-C021-4435-9667-145BD5A26594Q42288751-6DCC4138-5DCD-4D18-A214-09133BF93A51Q44273207-16587CF0-BC40-448D-98FC-46999CED9BA7Q44657323-977998B1-7B6A-4DFB-8DE1-A1DB133260F3Q46787137-EE73CE24-797F-4EF2-BB49-65EFCAF27FC5Q46894275-BF93839A-5C8F-482C-849F-6619C93B2DF9Q46915097-0C49BD2A-EAE2-4B97-B307-7F6F888FFA90Q47301152-92CAD87E-2E38-4183-838B-323E2BE2DA6AQ51330582-9AF93CBF-9FE4-4814-8BD7-251A3AF91A19Q51655379-CA48CEFC-5FE2-4D56-8A84-B7A1D239D0E0Q57486982-FA37BB56-69F9-4875-A4D8-BDDA8F0F6914Q57913856-B346999D-C840-4411-A6B1-6D86C5E87AFCQ58604471-C627FFDA-5D76-440C-B913-9740E132EA70Q60174360-2B45A582-78CF-46FC-91C6-6607ED208028Q67516271-CCC5988E-D18F-43DA-8B8D-AE80C2FB3220Q70043281-8AEB5EBA-D4C6-4B21-887D-474E889E6B6CQ70045842-336922CA-913D-4FF0-903E-8CC47C4A2C89Q70722764-C2DA655A-B96C-47CA-AB1C-0A9E6FD4831BQ73511186-D16B4421-95D5-4B59-BB93-2BF95EEEE131
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas Borody
@ast
Thomas Borody
@en
Thomas Borody
@es
Thomas Borody
@nl
Thomas Borody
@sl
type
label
Thomas Borody
@ast
Thomas Borody
@en
Thomas Borody
@es
Thomas Borody
@nl
Thomas Borody
@sl
prefLabel
Thomas Borody
@ast
Thomas Borody
@en
Thomas Borody
@es
Thomas Borody
@nl
Thomas Borody
@sl
P106
P1153
24529556700
P21
P31
P496
0000-0002-0519-4698